Theravance Biopharma, Inc.
Assets & Liabilities
| Period | Total Liabilities | Total Assets | Cash on Hand |
|---|---|---|---|
| Mar 2017 | $294.1M | $588.0M | $169.9M |
| Jun 2017 | $302.8M | $543.9M | $139.6M |
| Sep 2017 | $302.0M | $486.2M | $91.3M |
| Dec 2017 | $326.2M | $441.4M | $89.0M |
| Mar 2018 | $416.7M | $480.1M | $125.8M |
| Jun 2018 | $387.0M | $421.4M | $103.9M |
| Sep 2018 | $384.4M | $371.0M | $101.2M |
| Dec 2018 | $611.8M | $560.2M | $378.0M |
| Mar 2019 | $644.5M | $531.3M | $223.2M |
| Jun 2019 | $629.7M | $492.4M | $178.3M |
| Sep 2019 | $628.1M | $445.3M | $102.4M |
| Dec 2019 | $632.7M | $408.8M | $58.1M |
| Mar 2020 | $763.3M | $605.4M | $332.8M |
| Jun 2020 | $766.7M | $564.3M | $104.7M |
| Sep 2020 | $773.7M | $512.2M | $93.3M |
| Dec 2020 | $772.8M | $469.1M | $81.5M |
| Mar 2021 | $748.3M | $375.1M | $114.0M |
| Jun 2021 | $729.6M | $429.3M | $204.9M |
| Sep 2021 | $726.7M | $403.1M | $121.4M |
| Dec 2021 | $713.4M | $374.8M | $90.0M |
| Mar 2022 | $706.8M | $355.4M | $94.4M |
| Jun 2022 | $710.6M | $360.8M | $87.3M |
| Sep 2022 | $282.9M | $763.5M | $418.5M |
| Dec 2022 | $165.6M | $607.4M | $298.2M |
| Mar 2023 | $168.0M | $538.6M | $187.7M |
| Jun 2023 | $166.5M | $446.6M | $105.6M |
| Sep 2023 | $167.5M | $413.6M | $71.7M |
| Dec 2023 | $169.0M | $382.0M | $39.5M |
| Mar 2024 | $166.4M | $371.3M | $53.8M |
| Jun 2024 | $168.3M | $362.0M | $46.3M |
| Sep 2024 | $170.5M | $356.1M | $23.4M |
| Dec 2024 | $178.6M | $354.2M | $37.8M |
| Mar 2025 | $177.6M | $343.6M | $110.6M |
| Jun 2025 | $201.2M | $426.0M | $281.9M |
| Sep 2025 | $182.8M | $415.5M | $174.8M |
| Dec 2025 | $188.8M | $485.6M | $167.8M |
| Mar 2026 | $181.7M | $472.3M | $288.1M |
| Jun 2026 | $180.1M | $469.8M | $219.8M |